LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAV⦠read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
$1.57
Price+0.66%
$0.01
$41.307m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$4.990m
-
1y CAGR-
3y CAGR-
5y CAGR-$28.383m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.05
-
1y CAGR-
3y CAGR-
5y CAGR$19.935m
$60.547m
Assets$40.612m
Liabilities-
Debt0.00%
-
Debt to EBITDA-$21.782m
-
1y CAGR-
3y CAGR-
5y CAGR